Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
作者: Julia StieglmaierJonathan BenjaminDirk Nagorsen
作者单位: 1Amgen Research (Munich), Global Clinical Development, Therapeutic Area Oncology , Staffelseestraße 2, Munich 81477, Germany
2Amgen Inc., Global Clinical Development, Therapeutic Area Oncology , 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA
3Amgen Inc., Early Development Oncology , 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA +1 805 447 3244 ; +1 805 480 1291 ; dirk.nagorsen@amgen.com
刊名: Expert Opinion on Biological Therapy, 2015, Vol.15 (8), pp.1093-1099
来源数据库: Taylor & Francis Journal
DOI: 10.1517/14712598.2015.1041373
关键词: Bispecific antibodyBiTE®BlinatumomabCancer immunotherapyT-cells
原始语种摘要: Various approaches of T-cell-based cancer immunotherapy are currently under investigation, among these are BiTE® (bispecific T-cell engager) antibody constructs, which have a unique design and mechanism of action. They are constructed by genetically linking onto a single polypeptide chain the minimal binding domains of monoclonal antibodies for tumor-associated surface antigens and for the T-cell receptor-associated molecule CD3. Concurrent engagement of the target cell antigen and CD3 leads to activation of polyclonal cytotoxic T-cells, resulting in target cell lysis. Blinatumomab, a BiTE targeting CD19, is being investigated in a broad range of B-cell malignancies and has recently been approved in the USA by the US FDA for Philadelphia chromosome-negative relapsed/refractory B-acute...
全文获取路径: Taylor & Francis  (合作)
影响因子:3.345 (2012)

  • immunotherapy 免疫疗法
  • antibody 抗体
  • platform 台地
  • engagement 啮合
  • monoclonal 单细胞系的
  • constructs 建筑图纸生成系统
  • cytotoxic 细胞毒素的
  • polyclonal 多元性繁殂系的
  • targeting 导向目标
  • cancer 癌症